KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient

Cited by (570)

Items 101–200 of 570

1. Change in Dyslipidemia with Declining Glomerular Filtration Rate and Increasing Proteinuria in Children with CKD.
   J. Saland, J. Kupferman, C. Pierce, J. Flynn, M. Mitsnefes, B. Warady, S. Furth · 2019 · American Society of Nephrology. Clinical Journal
2. Inverse Association Between Serum Non–High‐Density Lipoprotein Cholesterol Levels and Mortality in Patients Undergoing Incident Hemodialysis
   T. Chang, E. Streja, Gang-Jee Ko, Neda Naderi, C. Rhee, C. Kovesdy, M. Kashyap, N. Vaziri, K. Kalantar-Zadeh, H. Moradi · 2018 · Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease
3. Endothelial dysfunction in the kidney transplant population: Current evidence and management strategies
   A. Prabhahar, A. Batta, Juniali Hatwal, Vivek Kumar, R. Ramachandran, Akash Batta · 2025 · World journal of transplantation
4. The effect of statins on renal outcomes in patients with diabetic kidney disease: A systematic review and meta‐analysis
   Xin Qin, Hui Dong, Ke Fang, Fu-Er Lu · 2017 · Diabetes/Metabolism Research Reviews
5. Dyslipidemia after pediatric renal transplantation—The impact of immunosuppressive regimens
   S. Habbig, R. Volland, K. Krupka, U. Querfeld, L. Dello Strologo, A. Noyan, F. Yalçınkaya, R. Topaloğlu, N. Webb, M. Kemper et al. · 2017 · Pediatric Transplantation
6. Prognostic role of LDL cholesterol in non-dialysis chronic kidney disease: Multicenter prospective study in Italy.
   L. De Nicola, M. Provenzano, P. Chiodini, G. D'Arrigo, G. Tripepi, L. Del Vecchio, G. Conte, F. Locatelli, C. Zoccali, R. Minutolo · 2015 · NMCD. Nutrition Metabolism and Cardiovascular Diseases
7. Effect of High-Dose Atorvastatin on Renal Function in Subjects With Stroke or Transient Ischemic Attack in the SPARCL Trial
   Pierre Amarenco, Alfred S. Callahan Iii, Vito M. Campese, Larry B. Goldstein, Michael G. Hennerici, Michael Messig, Henrik Hegaard Sillesen, Kenneth M. A. Welch, Daniel J. Wilson, Justin A. Zivin · 2014 · Stroke
8. AI-Driven Patient Education in Chronic Kidney Disease: Evaluating Chatbot Responses against Clinical Guidelines
   Prakrati C. Acharya, R. Maniega Alba, Pajaree Krisanapan, Chirag Acharya, Supawadee Suppadungsuk, Éva Csongrádi, Michael A. Mao, Iasmina M. Craici, Jing Miao, Charat Thongprayoon et al. · 2024 · Diseases
9. C3G and Ig-MPGN—treatment standard
   M. Noris, G. Remuzzi · 2023 · Nephrology, Dialysis and Transplantation
10. Association of anti-neutrophil cytoplasmic antibody-associated vasculitis and cardiovascular events: a population-based cohort study
    David Massicotte‐Azarniouch, William Petrcich, Michael W. Walsh, Mark Canney, Gregory L. Hundemer, Nataliya Milman, Michelle Hladunewich, Todd Fairhead, Manish M. Sood · 2021 · Clinical Kidney Journal
11. Chronic kidney disease measures for cardiovascular risk prediction
    Yejin Mok, Shoshana H. Ballew, Kunihiro Matsushita · 2021 · Atherosclerosis
12. Podocyte Lipotoxicity in CKD
    Jin‐Ju Kim, Sydney S. Wilbon, Alessia Fornoni · 2021 · Kidney360
13. Prevalence of Cardiovascular Disease Risk Factors in Childhood Glomerular Diseases
    Isa F. Ashoor, Sarah A. Mansfield, Michelle Marie O'Shaughnessy, Rulan Savita Parekh, Jarcy Zee, Tetyana L. Vasylyeva, Amy J. Kogon, Christine B. Sethna, Dorey A. Glenn, Aftab S. Chishti et al. · 2019 · Journal of the American Heart Association
14. Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis.
    V. Krane, Kay-Renke Schmidt, Lena J. Gutjahr-Lengsfeld, J. Mann, W. März, F. Swoboda, C. Wanner · 2016 · Kidney International
15. Triglyceride to High-Density Lipoprotein Cholesterol Ratio Predicts Cardiovascular Outcomes in Prevalent Dialysis Patients
    Hung‐Yuan Chen, Wan‐Chuan Tsai, Yen‐Ling Chiu, Shih‐Ping Hsu, Mei‐Fen Pai, Ju‐Yeh Yang, Yu‐Sen Peng · 2015 · Medicine
16. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
    Chiadi E. Ndumele, Fátima Rodríguez, Dave L. Dixon, Sadiya S. Khan, Debabrata Mukherjee, Mandeep Singh Bajaj, Sripal Bangalore, Biykem Bozkurt, Khadijah K Breathett, Shoa L. Clarke et al. · 2026 · Circulation
17. Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients
    H. Hwang, J. S. Kim, Y. Kim, So-Young Lee, S. Ahn, H. Lee, Dong-Young Lee, Sang-ho Lee, J. Moon, K. Jeong · 2020 · Journal of Clinical Medicine
18. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia
    Pragyi Shrestha, Bart van de Sluis, Robin P. F. Dullaart, Jacob van den Born · 2018 · Cellular Signalling
19. Clinical Studies of Interventions to Mitigate Cardiovascular Risk in Peritoneal Dialysis Patients.
    D. Jegatheesan, Yeoungjee Cho, David W. Johnson · 2018 · Seminars in Nephrology
20. Cholesterol-Lowering Agents
    Savvas Hadjiphilippou, Kausik Kumar Ray · 2019 · Circulation Research
21. Elevated TG/HDL-C and non-HDL-C/HDL-C ratios predict mortality in peritoneal dialysis patients
    Wen-Kai Xia, Xia-Juan Yao, Yan Chen, Jie Lin, V. Vielhauer, Hong Hu · 2020 · BMC Nephrology
22. The Role of Non-HDL Cholesterol and Apolipoprotein B in Cardiovascular Disease: A Comprehensive Review
    Vasiliki K. Katsi, Nikolaos Argyriou, Christos Fragoulis, Konstantinos P Tsioufis · 2025 · Journal of Cardiovascular Development and Disease
23. Treatment of dyslipidemia in kidney transplantation
    Claudio E. Ponticelli, Lorenzo Arnaboldi, Gabriella Luisa Moroni, Alberto Corsini · 2020 · Expert Opinion on Drug Safety
24. Cholesterol Disturbances and the Role of Proper Nutrition in CKD Patients
    Anna Gluba-Brzózka, Beata Franczyk, Jacek Rysz · 2019 · Nutrients
25. ESRD-induced dyslipidemia- Should management of lipid disorders differ in dialysis patients?
    H. Moradi, E. Streja, Nosratola D. Vaziri · 2018 · Seminars in dialysis
26. Prognostic value of bone- and vascular-derived molecular biomarkers in hemodialysis and renal transplant patients: a systematic review and meta-analysis
    Gernot Pichler, Maria C. Haller, Alexander Kainz, Myles Selig Wolf, Josep Redón, Rainer W. Oberbauer · 2016 · Nephrology Dialysis Transplantation
27. There is a U shaped association between non high density lipoprotein cholesterol with overall and cardiovascular mortality in chronic kidney disease stage 3–5
    Hsuan Chiu, Pei-Yu Wu, Jiun-Chi Huang, H. Tu, Ming-Yen Lin, Szu-Chia Chen, Jer-Ming Chang · 2020 · Scientific Reports
28. High-density lipoprotein cholesterol and causes of death in chronic kidney disease
    Sankar Dass Navaneethan, Jesse D. Schold, Carl Peter Walther, Susana Arrigain, Stacey E. Jolly, Salim S. Virani, Wolfgang C. Winkelmayer­, Joseph V. Nally · 2018 · Journal of clinical lipidology
29. Triglyceride Levels Are Closely Associated with Mild Declines in Estimated Glomerular Filtration Rates in Middle-Aged and Elderly Chinese with Normal Serum Lipid Levels
    Xin-Guo Hou, Chuan Wang, Xiu-ping Zhang, Xiangmin Zhao, Yu-Lian Wang, Cheng-Qiao Li, Mei Li, Shaoyuan Wang, Wei-Fang Yang, Zeqiang Ma et al. · 2014 · PLoS ONE
30. Statins, Mortality, and Major Adverse Cardiovascular Events Among US Veterans With Chronic Kidney Disease
    Odeya Barayev, Chelsea E. Hawley, Helen Wellman, Hanna Gerlovin, Whitney Hsu, Julie M. Paik, Ernest I. Mandel, Christine Liu, Luc Djoussé, J. Michael Gaziano et al. · 2023 · JAMA Network Open
31. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease
    Niki Katsiki, Dimitri P. Mikhailidis, Maciej Banach · 2019 · Expert Opinion on Pharmacotherapy
32. EQ-5D-Y for the assessment of health-related quality of life among Taiwanese youth with mild-to-moderate chronic kidney disease
    Chien-Ning Hsu, Hsiang-Wen Lin, A. S. Pickard, Y. Tain · 2018 · International Journal for Quality in Health Care
33. Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update
    Nasreen Alsayed, Wael A. Almahmeed, Fahad Alnouri, Khalid Al-Waili, Hani Mohamed Sabbour, Kadhim Sulaiman, Mohammad Zubaid, Kausik Kumar Ray, Khalid Al‐Rasadi · 2021 · Atherosclerosis
34. Proprotein convertase subtilisin/kexin type 9 in kidney disease
    David Schmit, Danilo Fliser, Thimoteus Speer · 2019 · Nephrology Dialysis Transplantation
35. The endothelial-to-mesenchymal transition and endothelial cilia in EPC-mediated postischemic kidney protection
    Daniel Patschan, Katrin Schwarze, Elvira Henze, Susann A. Patschan, Gerhard Anton Muller · 2016 · American Journal of Physiology-Renal Physiology
36. Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates.
    M. Schneider, Silvia Hübner, S. Titze, M. Schmid, J. Nadal, G. Schlieper, M. Busch, S. Baid-Agrawal, V. Krane, C. Wanner et al. · 2015 · Kidney International
37. Adherence to multidisciplinary care in a prospective chronic kidney disease cohort is associated with better outcomes
    Pablo Rios, L. Solá, A. Ferreiro, R. Silvariño, Verónica Lamadrid, Laura Ceretta, L. Gadola · 2022 · PLoS ONE
38. Dyslipidemia in Renal Transplant Recipients
    Karolina Chmielnicka, Zbigniew Heleniak, Alicja Maria Dębska-Ślizień · 2022 · Transplantology
39. Increased LDL-cholesterol level is associated with deterioration of renal function in males
    A. Osanami, Marenao Tanaka, M. Furuhashi, H. Ohnishi, N. Hanawa, T. Yamashita, Norihito Moniwa, T. Miura · 2022 · Clinical Kidney Journal
40. Time‐dependent lipid profile inversely associates with mortality in hemodialysis patients – independent of inflammation/malnutrition
    T. Ebert, A. Qureshi, C. Lamina, J. Fotheringham, M. Froissart, K. Eckardt, D. Wheeler, J. Floege, F. Kronenberg, P. Stenvinkel · 2021 · Journal of Internal Medicine
41. Statins and Cardiovascular Disease Outcomes in Chronic Kidney Disease: Reaffirmation vs. Repudiation
    Chamberlain I. Obialo, Elizabeth Ofili, Keith C. Norris · 2018 · International Journal of Environmental Research and Public Health
42. Diabetes mellitus y riesgo cardiovascular. Actualización de las recomendaciones del Grupo de Trabajo de Diabetes y Riesgo Cardiovascular de la Sociedad Española de Diabetes (SED, 2018)
    Francisco Arrieta, Pedro Iglesias, Juan Pedro‐Botet, Antonio Becerra, Emilio Ortega, Juan Carlos Obaya, Andreu Nubiola, Gonzálo Fernando Maldonado, Maria del Mar Campos, Romina Petrecca et al. · 2018 · Clínica e Investigación en Arteriosclerosis
43. Vascular calcification: When should we interfere in chronic kidney disease patients and how?
    U. E. El Din, M. Salem, D. Abdulazim · 2016 · World Journal of Nephrology
44. Chronic Renal Failure and Cardiovascular Disease: A Comprehensive Appraisal
    Keren Skalsky, Arthur Shiyovich, Tali Steinmetz, Ran Kornowski · 2022 · Journal of Clinical Medicine
45. Lipidic profiles of patients starting peritoneal dialysis suggest an increased cardiovascular risk beyond classical dyslipidemia biomarkers
    Julia Hernández Lluesa, L. López-Romero, J. B. Monzó, Marta Roca Marugán, Iris Viejo Boyano, D. Rodríguez-Espinosa, Aina Gómez-Bori, Amparo Soldevila Orient, Ramón Devesa Such, Pilar Sánchez Pérez et al. · 2021 · Scientific Reports
46. Dyslipidemia in Patients with Kidney Disease
    Aneesha Thobani, Terry A. Jacobson · 2021 · Cardiology Clinics
47. Statin initiation and all-cause mortality in incident statin-naïve dialysis patients
    Ji Eun Kim, Sehoon Park, Myeong-Seok Kim, Sung Jin Kang, Jang Wook Lee, Kwangsoo Kim, Yong Chul Kim, Dong Ki Kim, Kwon Wook Joo, Yon Su Kim et al. · 2021 · Atherosclerosis
48. Randomized trial of an intensified, multifactorial intervention in patients with advanced‐stage diabetic kidney disease: Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT‐Japan)
    K. Shikata, M. Haneda, T. Ninomiya, D. Koya, Yoshiki Suzuki, Daisuke Suzuki, Hitoshi Ishida, H. Akai, Y. Tomino, T. Uzu et al. · 2020 · Journal of Diabetes Investigation
49. The Pillars for Renal Disease Treatment in Patients with Type 2 Diabetes
    Jessica Kearney, Luigi Gnudi · 2023 · Pharmaceutics
50. Pemafibrate Protects against Fatty Acid-Induced Nephropathy by Maintaining Renal Fatty Acid Metabolism
    Daiki Aomura, M. Harada, Yosuke Yamada, Takero Nakajima, Koji Hashimoto, N. Tanaka, Y. Kamijo · 2021 · Metabolites
51. Potentially inappropriate prescribing in older adults with advanced chronic kidney disease
    Amber O. Molnar, Sarah E. Bota, Nivethika Jeyakumar, Eric McArthur, Marisa Battistella, Amit X. Garg, Manish M. Sood, Kenneth Scott Brimble · 2020 · PLoS ONE
52. Kidney-Secreted Erythropoietin Lowers Lipidemia via Activating JAK2-STAT5 Signaling in Adipose Tissue
    Jinxiang Li, Min-Liang Yang, Zhuo Yu, Jianwei Tian, Songlin Du, Hanying Ding · 2019 · EBioMedicine
53. Chronic kidney disease as a cardiovascular risk factor
    Rafael Carmena, Juan Francisco Ascaso, Josep Redón · 2020 · Journal of Hypertension
54. Medication Prescribing Quality in Australian Primary Care Patients with Chronic Kidney Disease
    W. Bezabhe, A. Kitsos, T. Saunder, G. Peterson, L. Bereznicki, B. Wimmer, M. Jose, J. Radford · 2019 · Journal of Clinical Medicine
55. Influence of the first radioactive iodine ablation on peripheral complete blood count in patients with differentiated thyroid cancer
    Tianpeng Hu, Z. Meng, Guizhi Zhang, Q. Jia, Jian Tan, Wei Zheng, Ren-Fei Wang, Xue Li, Na Liu, Ping-Ping Zhou et al. · 2016 · Medicine
56. Meta-analysis of statin therapy in maintenance dialysis patients
    Ling Sun, L. Zou, Mao-Jie Chen, Bi-Cheng Liu · 2015 · Renal Failure
57. Comprehensive Review of Lipid Management in Chronic Kidney Disease and Hemodialysis Patients: Conventional Approaches, and Challenges for Cardiovascular Risk Reduction
    Erica Abidor, Michel Al Achkar, Ibrahim Al Saidi, Tanvi Lather, Jennifer Jdaidani, Alaukika Agarwal, Suzanne El‐Sayegh · 2025 · Journal of Clinical Medicine
58. Ezetimibe Enhances Lipid Droplet and Mitochondria Contact Formation, Improving Fatty Acid Transfer and Reducing Lipotoxicity in Alport Syndrome Podocytes
    Jin-Ju Kim, Eun-Jeong Yang, Judith Molina-David, Sunjoo Cho, Maria Ficarella, N. Pape, J. E. Schiffer, Rachel Njeim, Stephanie S Kim, Claudia Lo Re et al. · 2024 · International Journal of Molecular Sciences
59. Serum triglycerides level is independently associated with renal outcomes in patients with non-dialysis chronic kidney disease: Results from KNOW-CKD study
    Sang-He-On Suh, Tae Ryom Oh, Hong-Sang Choi, C. Kim, E. Bae, K. Oh, S. Han, S. Ma, S. Kim · 2022 · Frontiers in Nutrition
60. Blood Plasma Metabolites in Diabetes-Associated Chronic Kidney Disease: A Focus on Lipid Profiles and Cardiovascular Risk
    A. Lecamwasam, T. Mansell, E. Ekinci, R. Saffery, K. Dwyer · 2022 · Frontiers in Nutrition
61. New Approaches to Cardiovascular Disease and Its Management in Kidney Transplant Recipients
    F. Aziz, M. Jorgenson, N. Garg, Sandesh Parajuli, Maha A. Mohamed, Farhan Raza, D. Mandelbrot, A. Djamali, R. Dhingra · 2021 · Transplantation
62. Erythropoietin Hyporesponsiveness in Dialysis Patients: Possible Role of Statins
    Takeshi Hasegawa, Junhui Zhao, Douglas S. Fuller, Brian A. Bieber, Jarcy Zee, Hal Morgenstern, Norio Hanafusa, Masaomi Nangaku · 2017 · American Journal of Nephrology
63. Renal transplantation in adults
    T. Nieto, N. Inston, P. Cockwell · 2016 · British medical journal
64. Technique failure in Korean incident peritoneal dialysis patients: a national population-based study
    Shi-Na Lee, Hyunwook Kim, Kyoung-Hoon Kim, H. Hann, H. Ahn, Seung-Jung Kim, Duk-Hee Kang, K. Choi, Dong-Ryeol Ryu · 2016 · Kidney Research and Clinical Practice
65. Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions
    Tramontano, Daniele, Bini, Simone, Maiorca, Carlo, Di Costanzo, Alessia, Carosi, Martina, Castellese, Jacopo, Arizaj, Ina, Commodari, Daniela, Covino, Stella, Sansone, Giorgia et al. · 2025 · Drugs
66. Dyslipidemia in Peritoneal Dialysis: Implications for Peritoneal Membrane Function and Patient Outcomes
    Natalia Stepanova · 2024 · Biomedicines
67. TROPONIN ELEVATION AS A MANIFESTATION OF COVID-19 MYOCARDIAL INFLAMMATION ASSOCIATED WITH INCREASED MORTALITY
    Michelle D. Kelsey, A. Nelson, J. Green, C. Granger, E. Peterson, D. McGuire, N. Pagidipati · 2022 · Journal of the American College of Cardiology
68. Capitated versus fee-for-service reimbursement and quality of care for chronic disease: a US cross-sectional analysis
    S. Tummalapalli, M. Estrella, D. Jannat-Khah, S. Keyhani, S. Ibrahim · 2022 · BMC Health Services Research
69. Hyperlipidemia and mortality associated with diabetes mellitus co-existence in Chinese peritoneal dialysis patients
    Xin Wei, Yue-Qiang Wen, Qian Zhou, Xiao-Ran Feng, Fen-Fen Peng, Nian-Song Wang, Xiao-Yang Wang, Xian-Feng Wu · 2020 · Lipids in Health and Disease
70. Chronic kidney disease and statin eligibility
    Gloria Lena Vega, Jijia Wang, Scott M. Grundy · 2020 · Journal of clinical lipidology
71. Statins and atherosclerotic cardiovascular outcomes in patients on incident dialysis and with atherosclerotic heart disease
    J. Shavadia, Jonathan Wilson, Daniel Edmonston, A. Platt, P. Ephraim, Rasheeda K. Hall, B. Goldstein, L. Boulware, E. Peterson, J. Pendergast et al. · 2020 · American Heart Journal
72. Dyslipidemia in patients with chronic kidney disease: etiology and management.
    M. Dušejovská, M. Vecka, I. Rychlík, A. Žák · 2020 · Vnitrni lekarstvi
73. Vascular access‐related mortality in hemodialysis patients during and after hospitalization
    Yohana Gil Giraldo, Patricia Muñoz Ramos, P. Ruano, B. Quiroga · 2020 · Therapeutic apheresis and dialysis
74. Cholesterol-Lowering Treatment in Chronic Kidney Disease: Multistage Pairwise and Network Meta-Analyses
    Francisco Herrera‐Gómez, M. Montserrat Chimeno, Débora Martín-García, Frank Lizaraso-Soto, Álvaro Maurtua-Briseño-Meiggs, Jesús Grande-Villoría, Juan Bustamante‐Munguira, Éric Alamartine, Miquel Vilardell, Carlos Ochoa Sangrador et al. · 2019 · Scientific Reports
75. Management of lipids in adults with diabetes mellitus and nephropathy and/or chronic kidney disease: summary of joint guidance from the Association of British Clinical Diabetologists (ABCD) and the Renal Association (RA)
    Patrick Barry Mark, Peter H. Winocour, Caroline Day · 2017 · British Journal of Diabetes
76. Lipid Association of India (LAI) expert consensus statement on management of dyslipidaemia in Indians 2017: part 2
    S. Iyengar, Raman Puri, S. Narasingan, Devaki R. Nair, V. Mehta, J. Mohan, S. Wangnoo, Jamshed J. Dalal, V. Jha, S. Puri et al. · 2017
77. From Risk Assessment to Management: Cardiovascular Complications in Pre- and Post-Kidney Transplant Recipients: A Narrative Review
    T. Beaudrey, D. Bedo, Célia Weschler, S. Caillard, N. Florens · 2025 · Diagnostics
78. Fenofibrate and risk of end‐stage renal disease: A nationwide cohort study
    Young Youl Hyun, Kyung‐Soo Kim, Sangmo Hong, Kyungdo Han, Cheol‐Young Park · 2024 · Diabetes Obesity and Metabolism
79. The Predictive Value of Atherogenic Index of Plasma, Non- High Density Lipoprotein Cholesterol (Non-HDL-C), Non-HDL-C/HDL-C, and Lipoprotein Combine Index for Stroke Incidence and Prognosis in Maintenance Hemodialysis Patients
    Li-Jie Ma, Fang Sun, Kai-Yi Zhu, Qiuxia Han, Qian-Mei Sun · 2024 · Clinical Interventions in Aging
80. Developing a genetic testing panel for evaluation of morbidities in kidney transplant recipients
    B. M. Ma, N. Elefant, Martina Tedesco, K. Bogyo, N. Vena, Sarath Babu Krishna Murthy, Shiraz Bheda, Sandy Yang, Nikita Tomar, Jun Y. Zhang et al. · 2024 · Kidney International
81. Statins in Kidney Transplant Recipients: Usage, All-Cause Mortality, and Interactions with Maintenance Immunosuppressive Agents
    Sunjae Bae, JiYoon B. Ahn, Corey Joseph, Ryan Whisler, Mark A. Schnitzler, Krista L. Lentine, BERNARD S. KADOSH, Dorry Lidor Segev, Mara McAdams‐DeMarco · 2023 · Journal of the American Society of Nephrology
82. Hyperlipidemia and mortality in patients on peritoneal dialysis
    Xiao-Ran Feng, Xiao-Jiang Zhan, Yue-Qiang Wen, Fen-Fen Peng, Xiao-Yang Wang, Nian-Song Wang, Xian-Feng Wu, Jun-Nan Wu · 2022 · BMC Nephrology
83. Apolipoprotein B is a risk factor for end-stage renal disease
    Soie Kwon, Dong Ki Kim, Kook‐Hwan Oh, Kwon Wook Joo, Chun Soo Lim, Yon Su Kim, Seung Seok Han · 2019 · Clinical Kidney Journal
84. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease
    Iryna Schlackow, Seamus Kent, William Guy Herrington, Jonathan Emberson, Richard Haynes, Christina A. Reith, Rory Collins, Martin Landray, Alastair McIntosh Gray, Colin Baigent et al. · 2019 · Kidney International
85. Effects of Statin Use in Advanced Chronic Kidney Disease Patients
    Tao‐Min Huang, Vin‐Cent Wu, Yu‐Feng Lin, Jian‐Jhong Wang, Chih‐Chung Shiao, Likwang Chen, Shih‐Chieh Chueh, Eric Chueh, Shao‐Yu Yang, Tai‐Shuan Lai et al. · 2018 · Journal of Clinical Medicine
86. Statin therapy across the lifespan: evidence in major age groups
    Neil J. Stone, Alexander Turin, Jared Alexander Spitz, Christopher W. Valle, Sakina Kazmi · 2015 · Expert Review of Cardiovascular Therapy
87. Efficacy and safety of statin therapy in kidney transplant recipients: a systematic review and meta-analysis
    Ioannis Bellos, Παγώνα Λάγιου, Vassiliki Benetou, Smaragdi Marinaki · 2024 · Lipids in Health and Disease
88. Novel insights into modifiable risk factors for arteriovenous fistula failure and the importance of CKD lipid profile: A meta-analysis
    Shaonong Wei, Nai-Meng Liu, Ying-Li Fu, Mindan Sun · 2023 · Journal of Vascular Access
89. Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology
    Anne Zanchi, Andreas Werner Jehle, Faïza Lamine, Bruno Vogt, Cecilia Czerlau, Stefan Bilz, Harald Seeger, Sophie de Seigneux · 2023 · Swiss Medical Weekly
90. Functional training added to intradialytic cycling lowers low-density lipoprotein cholesterol and improves dialysis adequacy: a randomized controlled trial
    Špela Bogataj, J. Pajek, Jadranka Buturović Ponikvar, M. Pajek · 2020 · BMC Nephrology
91. Cardiovascular Risk Factors Accelerate Kidney Function Decline in Post−Myocardial Infarction Patients: The Alpha Omega Cohort Study
    Kevin Esmeijer, J. Geleijnse, J. de Fijter, E. Giltay, D. Kromhout, E. Hoogeveen · 2018 · Kidney International Reports
92. A Web-Based Platform to Collect Data from ESRD Patients Undergoing Dialysis: Methods and Preliminary Results from the Brazilian Dialysis Registry
    J. Lugon, P. Gordan, F. Thomé, A. Lopes, Yoshimi Watanabe, C. Tzanno, R. Sesso · 2018 · International Journal of Nephrology
93. Effects of Cholesterol Levels on Mortality in Patients with Long-Term Peritoneal Dialysis Based on Residual Renal Function
    Yen-Chung Lin, Yi-Chun Lin, Chiung-Chi Peng, Kuan-Chou Chen, Hsi-Hsien Chen, Te-Chao Fang, S. Sung, Mai-Szu Wu · 2018 · Nutrients
94. Different effect of hypercholesterolemia on mortality in hemodialysis patients based on coronary artery disease or myocardial infarction
    Yi-Chun Lin, Yen-Chung Lin, Hsi-Hsien Chen, T. Chen, Chih-Cheng Hsu, Chiung-Chi Peng, Mai-Szu Wu · 2016 · Lipids in Health and Disease
95. Association Between Poverty and Appropriate Statin Prescription for the Treatment of Hyperlipidemia in the United States: An Analysis From the ACC NCDR PINNACLE Registry
    Tanguturi, Varsha K., Kennedy, Kevin F., Virani, Salim S., Maddox, Thomas M., Armstrong, Katrina, Wasfy, Jason H. · 2020 · Cardiovascular Revascularization Medicine
96. Cardiovascular risk and chronic kidney disease: strategies for cardiac and renal protection. Interdisciplinary consensus
    Oksana M. Drapkina, Zhanna D. Kobalava, Marina Vladimirovna Shestakova, Irina Nikolaevna Bobkova, Ефремовцева Марина Алексеевна, Виллевальде Светлана Вадимовна, М. М. Batyushin, Yu. N. Belenkov, Andrey Vatazin, Albert S. Galyavich et al. · 2025 · CARDIOVASCULAR THERAPY AND PREVENTION
97. Effectiveness and safety of using statin therapy for the primary prevention of cardiovascular diseases in older patients with chronic kidney disease who are hypercholesterolemic: a target trial emulation study.
    Wan-Chun Xu, Y. Yau, Yanyu Pan, E. Tse, C. Lam, E. Wan · 2025 · The Lancet Healthy Longevity
98. Management of Elderly Patients with Chronic Kidney Disease
    Yohan Park, Won Min Hwang · 2024 · Yonsei Medical Journal
99. Hypertriglyceridemia is associated with decline of estimated glomerular filtration rate and risk of end-stage kidney disease in a real-word Italian cohort: Evidence from the TG-RENAL Study.
    R. Pontremoli, G. Desideri, M. Arca, P. Temporelli, V. Perrone, Melania Dovizio, C. Borghi, L. Esposti · 2023 · European journal of internal medicine
100. Association between intensity of statin therapy and mortality in persons with chronic kidney disease
     Carl Peter Walther, Peter Richardson, Salim S. Virani, Wolfgang C. Winkelmayer­, Sankar Dass Navaneethan · 2018 · Nephrology Dialysis Transplantation